Co-pay accumulators: A force to be reckoned with in 2019
Experts predict the controversial tactic will be deployed far more widely this year, significantly impacting manufacturers — and, whether or not they realize it yet, patients.
Commercial
Focus on drugs’ cost may prevent their discovery
Breakthrough drugs will eventually be more affordable, but a misplaced focus on their cost may prevent them from being discovered at all.
PhRMA spent nearly 10 times 2016’s sum on advertising last year
The group’s lobbying spend also doubled in 2017 as the Trump administration bore down on drug prices.
CEO: Marketing plan for anti-epileptic aims to distinguish it from sea of other cannabis drugs
A central component of the Epidiolex marketing strategy involves highlighting the drug’s efficacy and safety profile, not its precedent-setting CBD component.
Science behind Nobel winners spawned one of the biggest marketing duels in pharma history
The war on cancer took a big turn with the birth of checkpoint inhibitors. Laura Entis explores their scientific and commercial impact, the unanswered questions, and what’s next for this enormously successful group of immunotherapies.
A timeline of key moments in the development of checkpoint inhibitors
Immunotherapy’s modern era has been characterized by a tremendous amount of scientific and regulatory activity. Trace the road to the Nobel.
Pharma companies can address the opioid crisis by changing their approach to marketing
As pressure to address the opioid crisis mounts, pharma companies are evaluating their marketing strategies and tactics.
Half year pro ad report 2018: Journal ad pages jump 1.4%
Spending in medical journals during the first half of 2018 may not have reached the levels seen in the recent past. At the same time, pharma companies don’t appear to be trimming their investments.
FDA turns attention to vapes in latest version of Real Cost anti-tobacco campaign
An estimated 10.7 million teens are vaping or thinking about it.
With a nod from the FDA, Teva enters white-hot migraine market
Teva’s Ajovy becomes the second approved CGRP migraine therapy, following Amgen’s Aimovig.
Want to read more?
Please login or register first to view this content.
